ArticleOncogene2017
Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing.
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 83 citations in OpenAlex.
- Polo-like kinase 5 is lowly expressed and negatively correlates with poorer differentiation, and its positivity may predict a better prognosis in patients with colorectal cancer.Discover oncology · 2026Article
- Large-scale meta- and cross-trait analyses uncover shared genetic risk factors for IBS and psychiatric disorders.Frontiers in psychiatry · 2026Article
- DelSIEVE: cell phylogeny modeling of single nucleotide variants and deletions from single-cell DNA sequencing data.Genome biology · 2025Article
- Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment.Molecular cancer · 2025Review
- A benchmarking study of copy number variation inference methods using single-cell RNA-sequencing data.Precision clinical medicine · 2025Article
- Daxx Variation as a Potential Predictive Marker of the Therapeutic Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.Cancer medicine · 2025Article
- A novel golgi related genes based correlation prognostic index can better predict the prognosis of glioma and responses to immunotherapy.Discover oncology · 2025Article
- Research progress of colorectal cancer in genomic and transcriptomic at multi-level.Frontiers in genetics · 2025Review
- From Genomic Exploration to Personalized Treatment: Next-Generation Sequencing in Oncology.Current issues in molecular biology · 2024Review
- Mugen-UMAP: UMAP visualization and clustering of mutated genes in single-cell DNA sequencing data.BMC bioinformatics · 2024Article
- Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Single-cell phylogenies reveal changes in the evolutionary rate within cancer and healthy tissues.Cell genomics · 2023Article
- Advances in SEMA3F regulation of clinically high-incidence cancers.Cancer biomarkers : section A of Disease markers · 2023Article
- Association of LAMA1 Single-Nucleotide Polymorphisms with Risk of Esophageal Squamous Cell Carcinoma among the Eastern Chinese Population.Journal of oncology · 2023Article
- SIEVE: joint inference of single-nucleotide variants and cell phylogeny from single-cell DNA sequencing data.Genome biology · 2022Article
- Intestinal cellular heterogeneity and disease development revealed by single-cell technology.Cell regeneration (London, England) · 2022Review
- Automated histological classification for digital pathology images of colonoscopy specimen via deep learning.Scientific reports · 2022Article
- High-throughput single-сell sequencing in cancer research.Signal transduction and targeted therapy · 2022Review
- Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.Oncogene · 2022Article
- Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis.Signal transduction and targeted therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently single-cell whole-exome sequencing (scWES) has deeply expanded and sharpened our knowledge of cancer evolution and subclonality. Herein, with scWES and matched bulk whole-exome sequencing (bulk WES) on two colorectal cancer (CRC) patients with normal or adenomatous polyps, we found that both the adenoma and cancer were of monoclonal origin, and both shared partial mutations in the same signaling pathways, but each showed a specific spectrum of heterogeneous somatic mutations. In addition, the adenoma and cancer further developed intratumor heterogeneity with the accumulation of nonrandom somatic mutations specifically in GPCR, PI3K-Akt and FGFR signaling pathways. We identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution. In summary, we demonstrated that both colorectal adenoma and CRC are monoclonal in origin, and the CRCs further diversified into different subclones with heterogeneous mutation profiles accumulating in GPCR, PI3K-Akt and FGFR signaling pathways. ScWES provides evidence for the importance of mutations in certain pathways that would not be as apparent from bulk sequencing of tumors, and can potentially establish whether specific mutations are mutually exclusive or occur sequentially in the same subclone of cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.